2022, Number 2
<< Back Next >>
Med Int Mex 2022; 38 (2)
About the paper Risk factors of hepatocellular carcinoma in patients with chronic hepatitis C virus infection receiving pegylated interferon ribavirin treatment
Navarro-Yparraguirre MM, Arias-Revilla JC, Roque-Quezada E
Language: Spanish
References: 7
Page: 476-478
PDF size: 462.63 Kb.
Text Extraction
No abstract.
REFERENCES
Tobar M, López J. Factores de riesgo de carcinoma hepatocelular en pacientes con infección crónica por virus de hepatitis C en tratamiento con interferón pegilado-ribavirina. Med Interna México 2021; 37 (4): 469-74. https://doi. org/10.24245/mim.v37i4.3868
Alter MJ. Epidemiology of hepatitis C virus infection. World J Gastroenterol 2007; 13 (17): 2436-41. doi: 10.3748/wjg. v13.i17.2436.
Mohd Hanafiah K, Groeger J, Flaxman AD, Wiersma ST. Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatol 2013; 57 (4): 1333-42.
Perz JF, Armstrong GL, Farrington LA, Hutin YJF, Bell BP. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol 2006; 45 (4): 529-38. doi: 10.1016/j. jhep.2006.05.013.
Pawlotsky J-M, Feld JJ, Zeuzem S, Hoofnagle JH. From non-A, non-B hepatitis to hepatitis C virus cure. J Hepatol 2015; 62 (1 Suppl): S87-99. https://doi.org/10.1016/j. jhep.2015.02.006.
Flemming JA, Kim WR, Brosgart CL, Terrault NA. Reduction in liver transplant wait-listing in the era of direct-acting antiviral therapy. Hepatol 2017; 65 (3): 804-12. doi: 10.1002/ hep.28923.
Wong RJ, Singal AK. Trends in liver disease etiology among adults awaiting liver transplantation in the United States, 2014-2019. JAMA Netw Open 2020; 3 (2): e1920294. doi:10.1001/jamanetworkopen.2019.20294
Full text